Search clinical trials for: PTI-801

Total 5366 results

Proteostasis Therapeutics, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of PTI-808, PTI-801, and PTI-428 Combination Therapy in Subjects With Cystic Fibrosis

Cystic Fibrosis

United Kingdom
Proteostasis Therapeutics, Inc.

Completed

Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis

Healthy Volunteer - Complete | Cystic Fibrosis - Complete

United States, Belgium, United Kingdom, France, Germany, Canada, Denmark, New Zealand, Australia
Proteostasis Therapeutics, Inc.

Completed

Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis

Cystic Fibrosis | Healthy Volunteer

United States, Canada, Denmark, Germany, Sweden
National Taiwan University Hospital Hsin-Chu Branch

Not yet recruiting

Comparative Efficacy of Different Time Interval Between rTMS and Rehabilitation Program for Motor Recovery in Stroke Patients

Stroke

Taiwan
Modulation Therapeutics, Inc.
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma

Uveal Melanoma | Metastatic

United States
Seoul National University Hospital
Pharos iBio Co., Ltd.

Recruiting

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML

Relapsed or Refractory Acute Myeloid Leukemia

Korea, Republic of
Bioventus LLC

Active, not recruiting

Safety Study of PTP-001 for Treating Knee Osteoarthritis

Knee Osteoarthritis

United States
Elixir Medical Corporation
European Cardiovascular Research Center

Terminated

DESolve® X-Pand Global Post Market Registry (X-Pand)

Coronary Artery Stenosis

Germany, Netherlands
Universitätsklinikum Hamburg-Eppendorf

Recruiting

Nasotracheal Intubation in Critically Ill. (NaTra-P)

Critical Care | Tracheal Intubation Morbidity

Germany
NewG Lab Pharma

Active, not recruiting

KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma | Fibrolamellar Carcinoma

Korea, Republic of
Pain Therapeutics

Completed

Long-term Safety of PF-00345439 (Oxycodone)

Pain
Aclaris Therapeutics, Inc.

Completed

ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis

Alopecia

United States
Bioventus LLC
NBCD A/S

Active, not recruiting

Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis

Osteoarthritis, Knee

Australia, Canada, Denmark
University of Virginia

Terminated

Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma

United States
Pain Therapeutics
PRA Health Sciences

Completed

Nasal Human Abuse Potential of PTI-821

Opioid Abuse Nondependent

United States
Johnson & Johnson K.K. Medical Company

Completed

A Clinical Investigation of SM-01 Stenting Versus PTA for the Treatment of Superficial Femoral Artery Disease

Peripheral Vascular Diseases

Japan
Seoul National University Hospital
Pharos iBio Co., Ltd.

Recruiting

Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial) (CREATIVE)

Platinum-resistant Ovarian Cancer | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-refractory Ovarian Carcinoma

Korea, Republic of
Robert Lowsky
National Cancer Institute (NCI); Janssen, LP; The Leukemia and Lymphoma Society; Rising Tide Foundation

Completed

TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States
EGEN, Inc.

Terminated

A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients

Colorectal Cancer

United States
Pain Therapeutics
National Institute on Aging (NIA)

Completed

A Safety Study of PTI-125 in Healthy Volunteers

Alzheimer Disease | Alzheimer Disease, Early Onset

United States
Oregon Research Institute

Completed

Transitional Treatment of Adolescents in Family Therapy (Transitions)

Substance Abuse

United States
Maastricht University Medical Center
Winclove Bio Industries BV

Completed

The Effect of a Multispecies Probiotic on Hypersensitivity in Irritable Bowel Syndrome (IBS) Patients

Hypersensitivity | Irritable Bowel Syndrome

Netherlands
Terns, Inc.

Completed

DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis

NASH - Nonalcoholic Steatohepatitis

United States
Phoenix Tissue Repair, Inc.
Phoenix Tissue Repair, a BridgeBio company

Completed

Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01)

Recessive Dystrophic Epidermolysis Bullosa

United States
Phoenix Tissue Repair, Inc.

Completed

A Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa

Recessive Dystrophic Epidermolysis Bullosa

United States
Aalto University
Turku University Hospital; Helsinki University Central Hospital; Business Finland

Active, not recruiting

The Effects of Videogames on Depression Symptoms and Brain Dynamics

Major Depressive Disorder

Finland
Phoenicis Therapeutics

Recruiting

Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States
Kukje Pharma

Completed

[KSR-001-P01]Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristic of KSR-001

Dry Eye Syndromes

Korea, Republic of
Cassava Sciences, Inc.

Enrolling by invitation

Open-label Extension for Phase 3 Clinical Trials of Simufilam

Alzheimer Disease

United States, Canada, Puerto Rico
Proteostasis Therapeutics, Inc.

Completed

Study Assessing PTI-428 Safety, Tolerability, Pharmacokinetics and Effect in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States
Hoffmann-La Roche

Recruiting

Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

Alzheimers Disease

Korea, Republic of, United States, Canada, Poland, Spain, Australia, Japan, Chile, United Kingdom
Ixchelsis Limited

Completed

IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT), Patient Reported Outcomes and Safety in Men With Premature Ejaculation (PE)

Premature Ejaculation

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD

Attention Deficit Disorder With Hyperactivity

United States
Shanghai Changzheng Hospital

Not yet recruiting

A Clinical Trial for the Safety and Efficacy of CD-801 in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma
Proteostasis Therapeutics, Inc.

Completed

Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Canada, France, Denmark, Germany
Alzheon Inc.
Quotient Clinical

Completed

Single Dose Study of ALZ-801 Prototype Tablets

Alzheimer Disease
Oncolys BioPharma Inc

Unknown

A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors

Solid Tumor

United States
Alzheon Inc.

Active, not recruiting

Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease

Early Alzheimer's Disease

Netherlands, Czechia
Phoenix Tissue Repair, Inc.

Completed

A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB) (PTR-01-001)

Recessive Dystrophic Epidermolysis Bullosa

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant

Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Recurrent Chronic Lymphocytic Leukemia

United States
Alzheon Inc.

Not yet recruiting

Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects (APOLLOE4-LTE)

Early Alzheimer's Disease

United States, Canada, United Kingdom
Fundación Pública Andaluza para la gestión de la...

Completed

Andalusian Experience in the Use of Fostamatinib in Patients With ITP. FOSTASUR Study

Primary Immune Thrombocytopenia

Spain
Centre Hospitalier Universitaire de Nice

Completed

Drug-Eluting Balloon Angioplasty for the Treatment of Hemodialysis Vascular Access Stenosis (DEBAVAS) (B3AV)

Dysfunction of Hemodialysis Vascular Access (Fistula and Graft)

France
Altimmune, Inc.

Completed

Efficacy and Safety of ALT-801 in the Treatment of Obesity

Obesity/Overweight

United States
Stemline Therapeutics, Inc.

Completed

A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors

Solid Tumors

United States
Oscotec Inc.
PPD

Completed

Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States
Altimmune, Inc.

Completed

ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)

Type 2 Diabetes

United States
Altimmune, Inc.

Completed

ALT-801 in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability

NASH - Nonalcoholic Steatohepatitis

Australia
Shanghai Synergy Pharmaceutical Sciences Co., Ltd.

Not yet recruiting

Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Characteristics of HHT120 in Healthy Subjects (HHT120)

Healthy

China
Pain Therapeutics
National Institute on Aging (NIA)

Completed

PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

Alzheimer Disease

United States

Search clinical trials for: PTI-801

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations